REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

This study is evaluating repotrectinib — a targeted drug — specifically in patients with ROS1-positive non-small cell lung cancer (NSCLC) who have active brain metastases. ROS1 is a genetic mutation that drives some lung cancers, and repotrectinib is designed to cross the blood-brain barrier and attack cancer cells in both the lungs and brain. **You may be eligible if...** - You are 18 years or older - You have non-small cell lung cancer confirmed by biopsy with a ROS1 gene rearrangement (ROS1-positive) - You have active brain metastases (cancer that has spread to the brain), with or without symptoms - Immediate surgery or radiation to the brain is not required right now - You are able to swallow capsules whole **You may NOT be eligible if...** - Your lung cancer does not have a ROS1 mutation - You require immediate brain surgery or radiation for your brain metastases - You have serious organ dysfunction or other medical conditions that prevent safe treatment Talk to your doctor to see if this trial is right for you.